Patara Pharma
Patara Pharma is a privately held biotechnology company founded in 2013 and based in San Diego, California. The company operates in the healthcare industry, though its current operational status and specific product focus are not documented in available sources.
- Company typePrivate
- Founded2013
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Patara Pharma firmographics
Firmographics- Name
- Patara Pharma
- Website
- https://patarapharma.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Unknown
- Headcount range
- 1–10 employees
- Short description
- Patara Pharma is a privately held biotechnology company founded in 2013 and based in San Diego, California. The company operates in the healthcare industry, though its current operational status and specific product focus are not documented in available sources.
- Ownership category
- akta.pro rank
Patara Pharma industry classification
Industry- Product category
- Clinical-stage biopharmaceutical development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Mast Cell Disorders Specialty Care (HLAKAAAH)
- akta.pro secondary industry
- Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
Keywords
Where Patara Pharma is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Patara Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Patara Pharma product offering
Product offeringCore offering
Patara Pharma is a clinical-stage biotechnology company developing therapeutics for mast cell disorders. Market context from a DelveInsight report indicates the company's involvement in Phase 2/3 clinical development of elenestinib (BLU-263) as a treatment for indolent systemic mastocytosis, positioning the firm within the broader mastocytosis therapeutics market across the seven major markets (7MM).
Differentiator
Problem solved
Functional benefit
Companies that use Patara Pharma
Customer profileIdeal customer profiles1 record
Patara Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Patara Pharma partnerships and signals
Strategic signalScale indicators1 record
Patara Pharma competitors and assessment
Company assessmentEmerging players
- Allakos: Allakos develops therapeutics targeting mast cell and eosinophil-driven diseases. Comparable as a niche mast-cell-focused biotech pursuing inflammatory indications adjacent to systemic mastocytosis.
- Deciphera Pharmaceuticals: Deciphera developed ripretinib, a KIT/PDGFR inhibitor, and has worked on mast cell-related indications. Comparable as a small-molecule oncology player with KIT-pathway expertise relevant to mast cell disorders.
- Cogent Biosciences: Cogent Biosciences is developing bezuclastinib, a KIT inhibitor for systemic mastocytosis and other KIT-driven disorders. Comparable as an emerging targeted-therapy developer in the same indication space.
Regional players
- Cellular Biomedicine Group: Cellular Biomedicine is a small-cap cell-therapy developer with mast cell/allergy adjacency. Comparable as a small clinical-stage biotech in related inflammatory/immune indications.
Direct peers
- Blueprint Medicines: Blueprint Medicines is the leader in systemic mastocytosis with avapritinib (Ayvakit) approved and BLU-263 (elenestinib) in Phase 2/3 for indolent systemic mastocytosis. Directly comparable as a targeted-therapy developer in the same mast cell disorder indication Patara pursued.
- AB Science: AB Science develops masitinib for indolent systemic mastocytosis and severe mast cell activation disorders. Directly comparable small-molecule mast-cell-targeted therapy in the same clinical setting.
Broad incumbents
- Incyte Corporation: Incyte has KIT-inhibitor programs (e.g., INCB000928/infigratinib successor work) relevant to mast cell disorders. A larger oncology/biopharma with adjacent targeted-therapy R&D in the mast cell indication space.
- Novartis: Novartis markets midostaurin (Rydapt) for advanced systemic mastocytosis. A large incumbent with an approved mastocytosis therapy, providing the regulatory and commercial benchmark for any niche player like Patara.
Market position
Customer concentration
Patara Pharma social profiles
Digital presencePatara Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Patara Pharma leadership team
Management profileNumber of profiles
Patara Pharma funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Patara Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Patara Pharma
What does Patara Pharma do?
Patara Pharma is a clinical-stage biotechnology company developing therapeutics for mast cell disorders. Market context from a DelveInsight report indicates the company's involvement in Phase 2/3 clinical development of elenestinib (BLU-263) as a treatment for indolent systemic mastocytosis, positioning the firm within the broader mastocytosis therapeutics market across the seven major markets (7MM).
When was Patara Pharma founded?
Patara Pharma was founded in 2013. It employs 1 to 10 people.
Where is Patara Pharma based?
Patara Pharma is headquartered in San Diego, United States, in the North America region.
Who are Patara Pharma's main competitors?
Emerging players on record are Allakos, Deciphera Pharmaceuticals and Cogent Biosciences. Cellular Biomedicine Group is listed as a regional player. Direct peers are Blueprint Medicines and AB Science. Broad incumbents are Incyte Corporation and Novartis.
Does Patara Pharma have an API?
No public API is recorded for Patara Pharma.
What industry is Patara Pharma in?
Patara Pharma's product category is Clinical-stage biopharmaceutical development. Its primary akta.pro industry code is HLAKAAAH, Mast Cell Disorders Specialty Care, with a secondary code of HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.